Theravance Biopharma Balance Sheet - Annual (NASDAQ:TBPH)

Add to My Stocks
$27.01 $0.08 (0.3%) TBPH stock closing price Sep 18, 2018 (Closing)

A thorough fundamental analysis involves using data from Theravance Biopharma balance sheet, apart from other financial statements, to value the business. How cash on hand has increased or decreased is one of the many indicators used while undertaking the Theravance Biopharma stock analysis, and provides insights into the firm's financial performance. Annual results are typically accompanied with the company releasing financial statements. Apart from analyzing Theravance Biopharma revenue Theravance Biopharma operating cash flow, one needs to check balance sheet items like cash, fixed assets and debt. The Theravance Biopharma balance sheet for 2017 shows cash on hand of $88.98M. The company has a debt to equity ratio of 6.52.

View latest 10 year balance sheet data to check Theravance Biopharma financial performance.
show more
Quarterly
Annual
View Previous Years
View Next Years
Fiscal year is Jan - Dec201720162015201420132012
Cash88.98M344.7M112.7M89.21M--
Marketable Securities259.58M156.38M59.72M165.39M--
Receivables9.65M12.78M49.91M2.12M1.13M-
Inventory16.83M12.22M10M12.54M10.4M-
Raw Materials11.72M6.06M6.86M6.83M5.13M-
Work In Progress-2.62M----
Finished Goods5.03M3.52M3.13M5.57M4.9M-
Notes Receivable------
Other Current Assets3.7M2.4M5.11M6.08M2.56M-
Total Current Assets
378.74M528.5M237.47M275.37M14.1M-
Property Plant & Equipment56.87M52.7M----
Accumulated Depreciation46.71M44.24M----
Net Property Plant & Equipment
10.15M8.46M9.87M9.66M10.23M-
Investment & Advances41.58M99.56M50.86M51.39M--
Other Non-Current Assets------
Deferred Charges------
Intangibles------
Deposits & Other Assets10.9M2.72M1.91M1.33M--
Total Assets
441.4M639.25M300.11M337.77M25.17M-
Notes Payable------
Accounts Payable5.92M1.73M18.8M9.92M6.94M-
Current Portion Long-Term Debt------
Current Portion Capital Leases------
Accrued Expenses56.5M47.38M30.52M31.24M21.7M-
Income Taxes Payable------
Other Current Liabilities----8.2M-
Total Current Liabilities
62.55M49.26M49.47M41.25M36.85M-
Mortgages------
Deferred Taxes/Income3.66M3.96M4.59M5.15M4.77M-
Convertible Debt223.74M222.67M----
Long-Term Debt------
Non-Current Capital Leases------
Other Long-Term Liabilities36.25M13.11M2.98M1.57M--
Total Liabilities
326.22M289.02M57.05M47.98M42.21M-
Minority Interest------
Preferred Stock------
Common Stock Net------
Capital Surplus913.65M862.7M564.69M429.2M--
Retained Earnings-797.74M-512.22M-321.55M-139.33M-17.03M-
Treasury Stock------
Other Liabilities-0.73M-0.25M-0.07M-0.08M--
Shareholders Equity115.17M350.23M243.06M289.78M-17.03M-
Total Liabilities & Shareholders Equity441.4M639.25M300.11M337.77M25.17M-
All figures in USD. M: Millions of USD, B: Billions of USD.
View Previous Years
View Next Years

Most investors just check the Theravance Biopharma stock price, and Theravance Biopharma historical stock prices before investing. While share price is an important factor, one should also look at financials and valuation metrics like the Theravance Biopharma PE ratio chart. Below is a brief explanation of common balance sheet terms:

  • Assets: Anything that the Theravance Biopharma company owns and is a part of its books. Assets can be of three types: fixed, current and other assets which includes intangibles, advances. Internet companies typically don't have a lot of assets as there is not much investment in say machinery, equipment etc. Theravance Biopharma had total assets of $441.4M.
  • Liabilities include short term loans and long term loans availed by the company to fund its business operations. TBPH stock had total liabilities of $326.22M for the year 2017.

Theravance Biopharma Balance Sheet - Key Ratios

Current ratio
4.14
Debt to equity ratio
6.52
Asset turnover ratio
0.21
Receivables turnover
4.62
Price to book ratio
11.35

Annual Balance Sheets For Theravance Biopharma Inc Peers

Arrowhead Pharma balance sheet, Merck balance sheet, Pfizer balance sheet